NEWS FEED:09:05 AM Media Monitoring Tools 2026: Automating Reputation Management and Press Analysis • 04:57 PM Pavion Acquires Communication Company to Boost Midwest Footprint • 04:57 PM LivmorIQ Integrates CMS Blue Button Data to Bolster Medicare Retention • 04:57 PM Mixue Targets U.S. Tea Market with Low-Cost Strategy • 04:57 PM SciBase Secures $600,000 Order to Expand Castle Biosciences Partnership • 04:57 PM Cleveland’s Erieview Tower Secures $217 Million for Massive Redevelopment
Home › Releases › REGENXBIO Schedules September Investor Presentatio...

» Sections

Releases

REGENXBIO Schedules September Investor Presentations in New York

08.09.2026 14:197830
REGENXBIO Schedules September Investor Presentations in New York

REGENXBIO Inc. executives will headline a pair of investor fireside chats in New York this September to outline progress on their gene therapy pipeline. The Rockville-based firm aims to maintain market visibility as it advances late-stage clinical programs for rare and retinal diseases throughout the coming year.

The company’s leadership team is set to present at the Baird 2026 Global Healthcare Conference on September 15, followed by a session at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. Both events begin at 8:30 a.m. ET, with live webcasts available via the firm's investor relations portal. Replays will remain accessible for 30 days post-conference.

Since its 2009 founding, the company has focused on AAV gene therapy development. Current late-stage efforts include RGX-202 for Duchenne muscular dystrophy, and the ongoing partnership with Nippon Shinyaku for RGX-121 and RGX-111. Additionally, the firm continues its collaboration with AbbVie on surabgene lomparvovec, targeting wet AMD and diabetic retinopathy.

Share:TelegramXFacebook

Read Also

Comments (0)

Leave a comment

No comments yet. Be the first!